A share price of Cullinan Therapeutics Inc [CGEM] is currently trading at $11.6, up 6.72%. An important factor to consider is whether the stock is rising or falling in short-term value. The CGEM shares have gain 8.11% over the last week, with a monthly amount glided 16.23%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
On October 24, 2024, UBS initiated with a Buy rating and assigned a price target of $30 on the stock. Stifel started tracking the stock assigning a Buy rating and suggested a price target of $40 on May 01, 2024. William Blair initiated its recommendation with a Outperform. Wedbush started tracking with a Outperform rating for this stock on February 15, 2024, and assigned it a price target of $30. In a note dated June 15, 2023, TD Cowen initiated an Outperform rating.
Cullinan Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $5.68 and $13.33. Currently, Wall Street analysts expect the stock to reach $31 within the next 12 months. Cullinan Therapeutics Inc [NASDAQ: CGEM] shares were valued at $11.6 at the most recent close of the market. An investor can expect a potential return of 167.24% based on the average CGEM price forecast.
Analyzing the CGEM fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.45, Equity is -0.42 and Total Capital is -0.53. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Cullinan Therapeutics Inc [NASDAQ:CGEM] is 10.45. On the other hand, the Quick Ratio is 10.45, and the Cash Ratio is 3.15.
Transactions by insiders
Recent insider trading involved AHMED NADIM, President and CEO, that happened on Dec 23 ’25 when 9922.0 shares were sold. Chief Scientific Officer, Michaelson Jennifer completed a deal on Dec 19 ’25 to sell 1345.0 shares. Meanwhile, Chief Legal Officer SUMER JACQUELYN L sold 3480.0 shares on Dec 18 ’25.
